Fig. 8

Experimental validation of TMRS genes expression and DDAH1’s association with ccRCC malignancy (A) mRNA expression of 11 TMRS genes in 25 pairs of clinical ccRCC samples and matched adjacent normal tissues, assessed by qRT-PCR. (B) The Kaplan-Meier plot of patients with ccRCC in SRRSH cohort. The cutoff value was determined by surv_cutpoint function. (C) Protein expression levels of DDAH1 in 12 pairs of ccRCC and matched adjacent normal tissues from patients, evaluated through Western blot analysis. (D) Proliferative capacities of 786-O and Caki-1 cells transfected with DDAH1 siRNAs compared to siRNA control, determined by CCK-8 assays. E-F. Migration capabilities of 786-O and Caki-1 cells post-transfection with DDAH1 siRNAs or siRNA control, assessed using transwell assays. G. The kynurenine-to-tryptophan ratio in the cell supernatants of 786-O and Caki-1 cells treated with DDAH1 siRNAs or control siRNA. qRT-PCR, quantitative reverse transcription polymerase chain reaction; T, tumor; N, normal; SRRSH, Sir Run Run Shaw Hospital; NC, negative control; KD, knockdown; OD, optical density; P, patient; KYN, kynurenine; TRP, tryptophan; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001